Quest Holdings ( ATHEX ) NET DEBT
Δευτέρα 4 Ιουλίου 2022
Κυριακή 3 Ιουλίου 2022
Σάββατο 2 Ιουλίου 2022
Παρασκευή 1 Ιουλίου 2022
CLOU - ETF FOR THE FUTURE
CLOU - ETF FOR THE FUTURE by StockBlog on TradingView.com
After the big drop in tech stocks in recent months, this etf , that follows cloud companies, is a very good investment option for those who look to the future...
Πέμπτη 30 Ιουνίου 2022
Δευτέρα 27 Ιουνίου 2022
Κυριακή 26 Ιουνίου 2022
Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program
– Results from ongoing trials of VIR-2218 and VIR-3434 presented at the International
Liver Congress™ (ILC) 2022 demonstrate durable reductions in hepatitis B surface antigen with no safety signals –
– Company expects to dose first patient in Part B of the Phase 2 MARCH trial by the end of June –
SAN FRANCISCO, June 25, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from its robust hepatitis B virus (HBV) clinical trial program, including results from an ongoing Phase 2 clinical trial of VIR-2218, results from an ongoing Phase 1 clinical trial of VIR-3434 and preclinical data evaluating both investigational compounds as monotherapy and in combination. Data were presented in one oral and two poster presentations at the International Liver Congress™ (ILC) 2022, the Annual Meeting of the European Association for the Study of the Liver (EASL).
Εγγραφή σε:
Αναρτήσεις (Atom)